Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy

Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant (LBS-008; Belite Bio), an investigational once-daily oral therapy for Stargardt disease type 1 (STGD1)—a rare inherited retinal dystrophy for which no approved pharmacologic treatment currently exists. The filing, initiated in April 2026 and submitted under Breakthrough Therapy Designation (BTD), positions tinlarebant as a potential first-in-class therapy for a condition affecting an estimated 53,000 patients in the United States alone.¹

The completed NDA will now enter a 60-day FDA review period. If accepted for review, a PDUFA target action date will be assigned—a milestone that would formally begin the substantive regulatory evaluation and set a timeline for a potential approval decision.

"Stargardt disease places a profound burden on patients, often affecting them early in life and steadily diminishing central vision during critical years of education and independence," said Dr. Hendrik Scholl, Chief Medical Officer of Belite Bio in a press release. "We believe that the results from the phase 3 DRAGON trial, which demonstrated tinlarebant's ability to significantly reduce the growth rate of retinal lesions as compared to placebo, underscore its benefit and pave the way for it to potentially become the first approved therapy for this devastating disease."

NDA and regulatory pathway

The rolling submission was conducted under BTD, a designation granted by the FDA in recognition of the high unmet need in STGD1. Tinlarebant has also received Fast Track Designation and Rare Pediatric Disease Designation in the United States, as well as Orphan Drug Designation in the US, Europe, Japan, and Switzerland, and Sakigake Designation in Japan for STGD1. The NDA is supported principally by results from the phase 3 DRAGON trial (NCT05244304), which according to the company met its primary endpoint: a statistically significant reduction in the rate of retinal lesion growth compared to placebo. Full efficacy and safety data from DRAGON have not yet been published in peer-reviewed literature at the time of this report, limiting independent assessment of effect magnitude, confidence intervals, and the safety profile.

Clinical context and disease burden

STGD1 is the most common inherited macular dystrophy, caused by biallelic loss-of-function mutations in the ABCA4 gene, which encodes an ATP-binding cassette transporter critical for clearance of retinaldehyde derivatives from photoreceptors.² Defective ABCA4 function leads to toxic accumulation of bisretinoid compounds, including A2E, within retinal pigment epithelium (RPE) cells, driving progressive RPE and photoreceptor degeneration.² Disease onset typically occurs in the first or second decade of life, and most patients experience significant central visual acuity loss, with no current pharmacologic option to slow progression.³

Mechanism of action and drug background

Tinlarebant (also known as LBS-008) is a small-molecule inhibitor of retinol binding protein 4 (RBP4), the sole serum carrier protein responsible for transporting vitamin A (retinol) from the liver to peripheral tissues, including the retina. By reducing circulating RBP4 levels, tinlarebant limits retinol delivery to the eye, thereby attenuating the substrate availability for bisretinoid synthesis within the visual cycle.¹ This mechanism is conceptually distinct from gene therapy approaches targeting ABCA4 and does not require subretinal delivery.

Tinlarebant is also under investigation in geographic atrophy secondary to dry age-related macular degeneration, where bisretinoid accumulation is similarly implicated in RPE toxicity. An ongoing phase 3 trial (PHOENIX) and a phase 2/3 trial (DRAGON II) in STGD1 are active.

Interpretive considerations

The regulatory designations and DRAGON primary endpoint results suggest a clinically meaningful signal in a population with no therapeutic alternatives. However, the absence of peer-reviewed publication of the phase 3 data constrains independent evaluation of the benefit-risk profile. Retinal lesion growth rate, while a recognized structural endpoint in STGD1 research, has not previously served as the basis for an approved therapy, and FDA's acceptance and interpretation of this endpoint will be a key aspect of the review.³

Limitations and Next Steps

The 60-day filing review will determine whether the NDA is accepted and a PDUFA date assigned. Key outstanding questions include the magnitude and durability of lesion growth reduction, visual function outcomes, long-term safety data—particularly regarding systemic retinol suppression—and whether efficacy translates across the age spectrum of affected patients. Peer-reviewed publication of DRAGON trial data will be essential for independent clinical interpretation ahead of any approval decision.

References
1. Belite Bio, Inc. Belite Bio completes rolling submission of new drug application to US Food and Drug Administration for tinlarebant for the treatment of Stargardt disease type 1. GlobeNewswire. June 12, 2026. https://www.globenewswire.com/news-release/2026/06/13/3311366/0/en/belite-bio-completes-rolling-submission-of-new-drug-application-to-u-s-food-and-drug-administration-for-tinlarebant-for-the-treatment-of-stargardt-disease-type-1.html
2. Tsybovsky Y, Molday RS, Palczewski K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Adv Exp Med Biol. 2010;703:105-125. doi:10.1007/978
3. Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2017;101(1):25-30. doi:10.1136/bjophthalmol